Orouba Almilaji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Orouba Almilaji has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Jonathon Snook
Gastroenterology, Poole Hospital NHSFT, Poole, UK
5 shared publications Jonathon Snook
Gastroenterology Unit, Poole Hospital, University Hospitals Dorset NHS Foundation Trust, Poole, UK
3 shared publications- Karim Khaled
Department of Ophthalmology, Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut P.O. Box 11-3288, Lebanon
3 shared publications - Kate Walker
Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine , London
3 shared publications Ajay Aggarwal
Department of Health Service Research and Policy, Faculty of Public Health and Policy, LSHTM, London, UK; Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK
2 shared publicationsAlexandra Lewin
Department of Medical Statistics, Epidemiology and Public Health, LSHTM, London, UK
2 shared publications
Latest Publications
- 16 October 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-11
Waiting times and determinants of delay for head and neck cancer in England—a population cohort study using real world data
Background In Head and Neck Cancer (HNC), even short delays in treatment can worsen prognosis. We used real-world data to quantify waiting times and identify patient, tumour and health service factors associated with treatment delay in England. Methods Using linked national datasets (Cancer Registry, Cancer Waiting Times, Hospital Episodes Statistics, Radiotherapy and Chemotherapy), we calculated waiting times from referral to first treatment (surgery or (chemo)radiation) and used multivariable logistic regression models to examine factors associated with delay. Results Of 30,506 patients, 43% experienced treatment delay ( > 62 days from referral). Long delays ( > 90 days) affected 11% of patients treated with primary surgery and 20% of those receiving primary (chemo)radiation. Non-urgent referral (30% of patients) was the strongest predictor of long delay (aOR 4.07, CI: 3.54–4.68). Additional risk-factors included initial assessment at non-specialist (spoke) hospitals, non-oropharyngeal cancers, and higher socio-economic deprivation. Conclusions Treatment delays in HNC are worsening, particularly for patients treated with primary (chemo)radiation. Referral route is the strongest determinant. Interventions should focus on optimising referral pathways, increasing awareness of HNC symptoms among the public and primary care, and acknowledging the different drivers of delay associated with surgery and (chemo)radiation therapy.
- 16 October 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-11
Waiting times and determinants of delay for head and neck cancer in England—a population cohort study using real world data
Background In Head and Neck Cancer (HNC), even short delays in treatment can worsen prognosis. We used real-world data to quantify waiting times and identify patient, tumour and health service factors associated with treatment delay in England. Methods Using linked national datasets (Cancer Registry, Cancer Waiting Times, Hospital Episodes Statistics, Radiotherapy and Chemotherapy), we calculated waiting times from referral to first treatment (surgery or (chemo)radiation) and used multivariable logistic regression models to examine factors associated with delay. Results Of 30,506 patients, 43% experienced treatment delay ( > 62 days from referral). Long delays ( > 90 days) affected 11% of patients treated with primary surgery and 20% of those receiving primary (chemo)radiation. Non-urgent referral (30% of patients) was the strongest predictor of long delay (aOR 4.07, CI: 3.54–4.68). Additional risk-factors included initial assessment at non-specialist (spoke) hospitals, non-oropharyngeal cancers, and higher socio-economic deprivation. Conclusions Treatment delays in HNC are worsening, particularly for patients treated with primary (chemo)radiation. Referral route is the strongest determinant. Interventions should focus on optimising referral pathways, increasing awareness of HNC symptoms among the public and primary care, and acknowledging the different drivers of delay associated with surgery and (chemo)radiation therapy.
- 24 December 2025
- Published by Elsevier in Clinical Oncology
- Vol. 50, 104009
National Reporting of Bowel Cancer Care by the National Bowel Cancer Audit (NBOCA) Supports Hospital Teams to Improve care and Outcomes
- 24 December 2025
- Published by Elsevier in Clinical Oncology
- Vol. 50, 104009
National Reporting of Bowel Cancer Care by the National Bowel Cancer Audit (NBOCA) Supports Hospital Teams to Improve care and Outcomes
- Open Access
- 21 November 2025
- Published by Elsevier in Cancer Epidemiology
- Vol. 100, 102962
A clinical rule-based indicator to identify recurrence of colorectal cancer after curative resection using linked routinely collected national data
- 21 November 2025
- Published by Elsevier in Cancer Epidemiology
- Vol. 100, 102962
Open AccessA clinical rule-based indicator to identify recurrence of colorectal cancer after curative resection using linked routinely collected national data
- Open Access
- 6 March 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-10
Value of hospital administrative data linked to national cancer registry records to identify metastatic disease at time of primary diagnosis in colorectal cancer patients: a study using national data in England
Background: Routinely collected data are increasingly being used for cancer research and health service evaluation. For both purposes, accurately identifying metastatic disease at diagnosis is essential. We developed an approach to identify metastatic disease at time of primary diagnosis according to national hospital administrative data (HAD) in patients identified with colorectal cancer (CRC) in the English national cancer registry (CR). Methods: A national cohort of CRC patients diagnosed between 2013 and 2018 in England identified in CR data were linked to HAD. Metastatic disease was assumed to be present at diagnosis according to HAD if at least one of a set of pre-specified diagnostic ICD-10 codes appeared in a record of a hospital admission between one month before and six months after CRC diagnosis date. Results: Of 186,236 patients, 40,421 (21.7%) had metastatic cancer according to HAD, 42,843 (23.0%) according to CR data, 49,827 (26.8%) according to either data source, and 33,437 (18.0%) according to both. Metastatic information was missing in CR data in 14,065 patients and 1,930 of these (13.7%) had metastatic cancer according to HAD. 1-year mortality was 59.3% (95%-CI: 58.8 − 59.8%) in patients with metastatic disease and 7.4% (7.2 − 7.5%) in patients without if HAD and CR data agreed. Mortality fell between these results if HAD and CR data disagreed. High mortality was seen in patients with missing metastatic data in the CR: 74.4% (72.4 − 76.3%) in patients with metastatic disease and 45.2% (44.3-46.1%) in patients without metastatic disease according to HAD. Conclusions: HAD should be linked to CR data to provide more accurate information on metastatic CRC at diagnosis including sites of metastasis. Linkage to HAD increased the number of patients identified with metastatic CRC by 14%, compared to CR data alone. Patients with metastatic disease at diagnosis in either data source had mortality outcomes expected for patients with metastatic cancer. CRC patients with missing metastasis data in CR data are likely to have metastatic disease and linkage to HAD provides important prognostic information.
- 6 March 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-10
Open AccessValue of hospital administrative data linked to national cancer registry records to identify metastatic disease at time of primary diagnosis in colorectal cancer patients: a study using national data in England
Background: Routinely collected data are increasingly being used for cancer research and health service evaluation. For both purposes, accurately identifying metastatic disease at diagnosis is essential. We developed an approach to identify metastatic disease at time of primary diagnosis according to national hospital administrative data (HAD) in patients identified with colorectal cancer (CRC) in the English national cancer registry (CR). Methods: A national cohort of CRC patients diagnosed between 2013 and 2018 in England identified in CR data were linked to HAD. Metastatic disease was assumed to be present at diagnosis according to HAD if at least one of a set of pre-specified diagnostic ICD-10 codes appeared in a record of a hospital admission between one month before and six months after CRC diagnosis date. Results: Of 186,236 patients, 40,421 (21.7%) had metastatic cancer according to HAD, 42,843 (23.0%) according to CR data, 49,827 (26.8%) according to either data source, and 33,437 (18.0%) according to both. Metastatic information was missing in CR data in 14,065 patients and 1,930 of these (13.7%) had metastatic cancer according to HAD. 1-year mortality was 59.3% (95%-CI: 58.8 − 59.8%) in patients with metastatic disease and 7.4% (7.2 − 7.5%) in patients without if HAD and CR data agreed. Mortality fell between these results if HAD and CR data disagreed. High mortality was seen in patients with missing metastatic data in the CR: 74.4% (72.4 − 76.3%) in patients with metastatic disease and 45.2% (44.3-46.1%) in patients without metastatic disease according to HAD. Conclusions: HAD should be linked to CR data to provide more accurate information on metastatic CRC at diagnosis including sites of metastasis. Linkage to HAD increased the number of patients identified with metastatic CRC by 14%, compared to CR data alone. Patients with metastatic disease at diagnosis in either data source had mortality outcomes expected for patients with metastatic cancer. CRC patients with missing metastasis data in CR data are likely to have metastatic disease and linkage to HAD provides important prognostic information.
- Open Access
- 12 August 2024
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2024 (8) , CD014932
Educational and psychological interventions for managing atopic dermatitis (eczema)
Background Atopic dermatitis (eczema), can have a significant impact on well‐being and quality of life for affected people and their families. Standard treatment is avoidance of triggers or irritants and regular application of emollients and topical steroids or calcineurin inhibitors. Thorough physical and psychological assessment is central to good‐quality treatment. Overcoming barriers to provision of holistic treatment in dermatological practice is dependent on evaluation of the efficacy and economics of both psychological and educational interventions in this participant group. This review is based on a previous Cochrane review published in 2014, and now includes adults as well as children. Objectives To assess the clinical outcomes of educational and psychological interventions in children and adults with atopic dermatitis (eczema) and to summarise the availability and principal findings of relevant economic evaluations. Search methods We searched the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, APA PsycINFO and two trials registers up to March 2023. We checked the reference lists of included studies and related systematic reviews for further references to relevant randomised controlled trials (RCTs) and contacted experts in the field to identify additional studies. We searched NHS Economic Evaluation Database, MEDLINE and Embase for economic evaluations on 8 June 2022. Selection criteria Randomised, cluster‐randomised and cross‐over RCTs that assess educational and psychological interventions for treating eczema in children and adults. Data collection and analysis We used standard Cochrane methods, with GRADE to assess the certainty of the evidence for each outcome. Primary outcomes were reduction in disease severity, as measured by clinical signs, patient‐reported symptoms and improvement in health‐related quality‐of‐life (HRQoL) measures. Secondary outcomes were improvement in long‐term control of symptoms, improvement in psychological well‐being, improvement in standard treatment concordance and adverse events. We assessed short‐ (up to 16 weeks after treatment) and long‐term time points (more than 16 weeks). Main results We included 37 trials (6170 participants). Most trials were conducted in high‐income countries (34/37), in outpatient settings (25/37). We judged three trials to be low risk of bias across all domains. Fifteen trials had a high risk of bias in at least one domain, mostly due to bias in measurement of the outcome. Trials assessed interventions compared to standard care. Individual educational interventions may reduce short‐term clinical signs (measured by SCORing Atopic Dermatitis (SCORAD); mean difference (MD) −5.70, 95% confidence interval (CI) −9.39 to −2.01; 1 trial, 30 participants; low‐certainty evidence) but patient‐reported symptoms, HRQoL, long‐term eczema control and psychological well‐being were not reported. Group education interventions probably reduce clinical signs (SCORAD) both in the short term (MD −9.66, 95% CI −19.04 to −0.29; 3 studies, 731 participants; moderate‐certainty evidence) and the long term (MD −7.22, 95% CI −11.01 to −3.43; 3 studies, 1424 participants; moderate‐certainty evidence) and probably reduce long‐term patient‐reported symptoms (SMD −0.47 95% CI −0.60 to −0.33; 2 studies, 908 participants; moderate‐certainty evidence). They may slightly improve short‐term HRQoL (SMD −0.19, 95% CI −0.36 to −0.01; 4 studies, 746 participants; low‐certainty evidence), but may make little or no difference to short‐term psychological well‐being (Perceived Stress Scale (PSS); MD −2.47, 95% CI −5.16 to 0.22; 1 study, 80 participants; low‐certainty evidence). Long‐term eczema control was not reported. We don't know whether technology‐mediated educational interventions could improve short‐term clinical signs (SCORAD; 1 study; 29 participants; very low‐certainty evidence). They may have little or no effect on short‐term patient‐reported symptoms (Patient Oriented Eczema Measure (POEM); MD −0.76, 95% CI −1.84 to 0.33; 2 studies; 195 participants; low‐certainty evidence) and probably have little or no effect on short‐term HRQoL (MD 0, 95% CI −0.03 to 0.03; 2 studies, 430 participants; moderate‐certainty evidence). Technology‐mediated education interventions probably slightly improve long‐term eczema control (Recap of atopic eczema (RECAP); MD −1.5, 95% CI −3.13 to 0.13; 1 study, 232 participants; moderate‐certainty evidence), and may improve short‐term psychological well‐being (MD −1.78, 95% CI −2.13 to −1.43; 1 study, 24 participants; low‐certainty evidence). Habit reversal treatment may reduce short‐term clinical signs (SCORAD; MD −6.57, 95% CI −13.04 to −0.1; 1 study, 33 participants; low‐certainty evidence) but we are uncertain about any effects on short‐term HRQoL (Children's Dermatology Life Quality Index (CDLQI); 1 study, 30 participants; very low‐certainty evidence). Patient‐reported symptoms, long‐term eczema control and psychological well‐being were not reported. We are uncertain whether arousal reduction therapy interventions could improve short‐term clinical signs (Eczema Area and Severity Index (EASI); 1 study, 24 participants; very low‐certainty evidence) or patient‐reported symptoms (visual analogue scale (VAS); 1 study, 18 participants; very low‐certainty evidence). Arousal reduction therapy may improve short‐term HRQoL (Dermatitis Family Impact (DFI); MD −2.1, 95% CI −4.41 to 0.21; 1 study, 91 participants;...
- 12 August 2024
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2024 (8) , CD014932
Open AccessEducational and psychological interventions for managing atopic dermatitis (eczema)
Background Atopic dermatitis (eczema), can have a significant impact on well‐being and quality of life for affected people and their families. Standard treatment is avoidance of triggers or irritants and regular application of emollients and topical steroids or calcineurin inhibitors. Thorough physical and psychological assessment is central to good‐quality treatment. Overcoming barriers to provision of holistic treatment in dermatological practice is dependent on evaluation of the efficacy and economics of both psychological and educational interventions in this participant group. This review is based on a previous Cochrane review published in 2014, and now includes adults as well as children. Objectives To assess the clinical outcomes of educational and psychological interventions in children and adults with atopic dermatitis (eczema) and to summarise the availability and principal findings of relevant economic evaluations. Search methods We searched the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, APA PsycINFO and two trials registers up to March 2023. We checked the reference lists of included studies and related systematic reviews for further references to relevant randomised controlled trials (RCTs) and contacted experts in the field to identify additional studies. We searched NHS Economic Evaluation Database, MEDLINE and Embase for economic evaluations on 8 June 2022. Selection criteria Randomised, cluster‐randomised and cross‐over RCTs that assess educational and psychological interventions for treating eczema in children and adults. Data collection and analysis We used standard Cochrane methods, with GRADE to assess the certainty of the evidence for each outcome. Primary outcomes were reduction in disease severity, as measured by clinical signs, patient‐reported symptoms and improvement in health‐related quality‐of‐life (HRQoL) measures. Secondary outcomes were improvement in long‐term control of symptoms, improvement in psychological well‐being, improvement in standard treatment concordance and adverse events. We assessed short‐ (up to 16 weeks after treatment) and long‐term time points (more than 16 weeks). Main results We included 37 trials (6170 participants). Most trials were conducted in high‐income countries (34/37), in outpatient settings (25/37). We judged three trials to be low risk of bias across all domains. Fifteen trials had a high risk of bias in at least one domain, mostly due to bias in measurement of the outcome. Trials assessed interventions compared to standard care. Individual educational interventions may reduce short‐term clinical signs (measured by SCORing Atopic Dermatitis (SCORAD); mean difference (MD) −5.70, 95% confidence interval (CI) −9.39 to −2.01; 1 trial, 30 participants; low‐certainty evidence) but patient‐reported symptoms, HRQoL, long‐term eczema control and psychological well‐being were not reported. Group education interventions probably reduce clinical signs (SCORAD) both in the short term (MD −9.66, 95% CI −19.04 to −0.29; 3 studies, 731 participants; moderate‐certainty evidence) and the long term (MD −7.22, 95% CI −11.01 to −3.43; 3 studies, 1424 participants; moderate‐certainty evidence) and probably reduce long‐term patient‐reported symptoms (SMD −0.47 95% CI −0.60 to −0.33; 2 studies, 908 participants; moderate‐certainty evidence). They may slightly improve short‐term HRQoL (SMD −0.19, 95% CI −0.36 to −0.01; 4 studies, 746 participants; low‐certainty evidence), but may make little or no difference to short‐term psychological well‐being (Perceived Stress Scale (PSS); MD −2.47, 95% CI −5.16 to 0.22; 1 study, 80 participants; low‐certainty evidence). Long‐term eczema control was not reported. We don't know whether technology‐mediated educational interventions could improve short‐term clinical signs (SCORAD; 1 study; 29 participants; very low‐certainty evidence). They may have little or no effect on short‐term patient‐reported symptoms (Patient Oriented Eczema Measure (POEM); MD −0.76, 95% CI −1.84 to 0.33; 2 studies; 195 participants; low‐certainty evidence) and probably have little or no effect on short‐term HRQoL (MD 0, 95% CI −0.03 to 0.03; 2 studies, 430 participants; moderate‐certainty evidence). Technology‐mediated education interventions probably slightly improve long‐term eczema control (Recap of atopic eczema (RECAP); MD −1.5, 95% CI −3.13 to 0.13; 1 study, 232 participants; moderate‐certainty evidence), and may improve short‐term psychological well‐being (MD −1.78, 95% CI −2.13 to −1.43; 1 study, 24 participants; low‐certainty evidence). Habit reversal treatment may reduce short‐term clinical signs (SCORAD; MD −6.57, 95% CI −13.04 to −0.1; 1 study, 33 participants; low‐certainty evidence) but we are uncertain about any effects on short‐term HRQoL (Children's Dermatology Life Quality Index (CDLQI); 1 study, 30 participants; very low‐certainty evidence). Patient‐reported symptoms, long‐term eczema control and psychological well‐being were not reported. We are uncertain whether arousal reduction therapy interventions could improve short‐term clinical signs (Eczema Area and Severity Index (EASI); 1 study, 24 participants; very low‐certainty evidence) or patient‐reported symptoms (visual analogue scale (VAS); 1 study, 18 participants; very low‐certainty evidence). Arousal reduction therapy may improve short‐term HRQoL (Dermatitis Family Impact (DFI); MD −2.1, 95% CI −4.41 to 0.21; 1 study, 91 participants;...
- Open Access
- 26 June 2024
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 11 (1) , e001305
Role of prescribed medication in the development of iron deficiency anaemia in adults—a case–control study
Objective To estimate the strength of association between exposure to selected classes of prescribed medications and the risk of developing iron deficiency anaemia (IDA), specifically considering oral anticoagulants (OACs), antidepressants, antiplatelet agents, proton pump inhibitors (PPIs) and non-steroidal anti-inflammatories. Design A case–control study involving the analysis of community repeat prescriptions among subjects referred with IDA, and unmatched controls referred as gastroenterology fast-tracks for other indications. Multivariable logistic regression modelling was used to calculate ORs for the association between IDA presentation and each medication class, adjusted for age, sex and coprescribing. For those classes showing significance, it was also used to calculate risk differences between those in the IDA group with or without haemorrhagic lesions on investigation. Results A total of 1210 cases were analysed—409 in the IDA group, and 801 in the control group. Significant associations were identified between presentation with IDA and long-term exposure to PPIs (OR 3.29, 95% CI: 2.47 to 4.41, pConclusion Long-term exposure to PPIs and OACs are independently associated with the risk of developing IDA. There are grounds for considering that these associations may be causal, though the underlying mechanisms probably differ.
- 26 June 2024
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 11 (1) , e001305
Open AccessRole of prescribed medication in the development of iron deficiency anaemia in adults—a case–control study
Objective To estimate the strength of association between exposure to selected classes of prescribed medications and the risk of developing iron deficiency anaemia (IDA), specifically considering oral anticoagulants (OACs), antidepressants, antiplatelet agents, proton pump inhibitors (PPIs) and non-steroidal anti-inflammatories. Design A case–control study involving the analysis of community repeat prescriptions among subjects referred with IDA, and unmatched controls referred as gastroenterology fast-tracks for other indications. Multivariable logistic regression modelling was used to calculate ORs for the association between IDA presentation and each medication class, adjusted for age, sex and coprescribing. For those classes showing significance, it was also used to calculate risk differences between those in the IDA group with or without haemorrhagic lesions on investigation. Results A total of 1210 cases were analysed—409 in the IDA group, and 801 in the control group. Significant associations were identified between presentation with IDA and long-term exposure to PPIs (OR 3.29, 95% CI: 2.47 to 4.41, pConclusion Long-term exposure to PPIs and OACs are independently associated with the risk of developing IDA. There are grounds for considering that these associations may be causal, though the underlying mechanisms probably differ.
- Open Access
- 29 March 2023
- Published by Elsevier in Physiotherapy
- Vol. 120, 47-59
Frequency, duration, and type of physiotherapy in the week after hip fracture surgery – analysis of implications for discharge home, readmission, survival, and recovery of mobility
- 29 March 2023
- Published by Elsevier in Physiotherapy
- Vol. 120, 47-59
Open AccessFrequency, duration, and type of physiotherapy in the week after hip fracture surgery – analysis of implications for discharge home, readmission, survival, and recovery of mobility
- Open Access
The Development of a Clinical Decision-Support Web-Based Tool for Predicting the Risk of Gastrointestinal Cancer in Iron Deficiency Anaemia—The IDIOM App
To facilitate the clinical use of an algorithm for predicting the risk of gastrointestinal malignancy in iron deficiency anaemia—the IDIOM score, a software application has been developed, with a view to providing free and simple access to healthcare professionals in the UK. A detailed requirements analysis for intended users of the application revealed the need for an automated decision-support tool in which anonymised, individual patient data is entered and gastrointestinal cancer risk is calculated and displayed immediately, which lends itself to use in busy clinical settings. Human-centred design was employed to develop the solution, focusing on the users and their needs, whilst ensuring that they are provided with sufficient details to appropriately interpret the risk score. The IDIOM App has been developed using R Shiny as a web-based application enabling access from different platforms with updates that can be carried out centrally through the host server. The application has been evaluated through literature search, internal/external validation, code testing, risk analysis, and usability assessments. Legal notices, contact system with research and maintenance teams, and all the supportive information for the application such as description of the population and intended users have been embedded within the application interface. With the purpose of providing a guide of developing standalone software medical devices in academic setting, this paper aims to present the theoretical and practical aspects of developing, writing technical documentation, and certifying standalone software medical devices using the case of the IDIOM App as an example.
Open AccessThe Development of a Clinical Decision-Support Web-Based Tool for Predicting the Risk of Gastrointestinal Cancer in Iron Deficiency Anaemia—The IDIOM App
To facilitate the clinical use of an algorithm for predicting the risk of gastrointestinal malignancy in iron deficiency anaemia—the IDIOM score, a software application has been developed, with a view to providing free and simple access to healthcare professionals in the UK. A detailed requirements analysis for intended users of the application revealed the need for an automated decision-support tool in which anonymised, individual patient data is entered and gastrointestinal cancer risk is calculated and displayed immediately, which lends itself to use in busy clinical settings. Human-centred design was employed to develop the solution, focusing on the users and their needs, whilst ensuring that they are provided with sufficient details to appropriately interpret the risk score. The IDIOM App has been developed using R Shiny as a web-based application enabling access from different platforms with updates that can be carried out centrally through the host server. The application has been evaluated through literature search, internal/external validation, code testing, risk analysis, and usability assessments. Legal notices, contact system with research and maintenance teams, and all the supportive information for the application such as description of the population and intended users have been embedded within the application interface. With the purpose of providing a guide of developing standalone software medical devices in academic setting, this paper aims to present the theoretical and practical aspects of developing, writing technical documentation, and certifying standalone software medical devices using the case of the IDIOM App as an example.
- Open Access
- 1 March 2022
- Published by Medknow in Saudi Journal of Gastroenterology
- Vol. 28 (2) , 115-121
Modelling the episodes of care for iron deficiency anemia patients in a secondary-care center using continuous-time multistate Markov chain
Background: Despite the high prevalence of gastro-intestinal (GI) cancer in iron deficiency anemia (IDA), some IDA patients do not complete all the necessary GI investigations at the initial referral. As a result, existing cancers are diagnosed at a later referral with worse prognosis. The potential to detect GI cancer early depends on minimizing the delay time spent between the two consecutive referrals, where a patient did not complete investigations at the first referral, but at the second is diagnosed with positive GI cancer. This retrospective longitudinal study aims to highlight the proper methods to model these referrals. Methods: Using anonymized data of 168 episodes of care for IDA patients at an IDA clinic in a secondary care setting, continuous-time multi-state Markov chain is employed to determine the transition rates among three observed states for IDA patients at the IDA clinic, “incomplete investigations,” “negative GI cancer,” and “positive GI cancer” and to estimate the delay time. Results: Once in the state of incomplete investigations, an estimated mean delay time of 3.1 years (95% CI: 1.2, 5) is spent before being diagnosed with positive GI cancer. The probability that a “positive GI diagnosis” is next after the state of “incomplete investigation” is 17%, compared with 11% when it is followed in the state of negative GI cancer. Defining the survival as the event of not being in the state of “positive GI cancer,” the survival rate of IDA patients with negative GI cancer is always higher than those with incomplete investigations. Finally, being diagnosed with positive GI cancer is always preceded by the prediction of being considered “very high risk” at the earlier visit. Conclusion: A baseline model was proposed to represent episodes of care for IDA patients at a secondary care center. Preliminary results highlight the importance of completing the GI investigations, especially in IDA patients, who are at high risk of GI cancer and fit to go through the investigations.
- 1 March 2022
- Published by Medknow in Saudi Journal of Gastroenterology
- Vol. 28 (2) , 115-121
Open AccessModelling the episodes of care for iron deficiency anemia patients in a secondary-care center using continuous-time multistate Markov chain
Background: Despite the high prevalence of gastro-intestinal (GI) cancer in iron deficiency anemia (IDA), some IDA patients do not complete all the necessary GI investigations at the initial referral. As a result, existing cancers are diagnosed at a later referral with worse prognosis. The potential to detect GI cancer early depends on minimizing the delay time spent between the two consecutive referrals, where a patient did not complete investigations at the first referral, but at the second is diagnosed with positive GI cancer. This retrospective longitudinal study aims to highlight the proper methods to model these referrals. Methods: Using anonymized data of 168 episodes of care for IDA patients at an IDA clinic in a secondary care setting, continuous-time multi-state Markov chain is employed to determine the transition rates among three observed states for IDA patients at the IDA clinic, “incomplete investigations,” “negative GI cancer,” and “positive GI cancer” and to estimate the delay time. Results: Once in the state of incomplete investigations, an estimated mean delay time of 3.1 years (95% CI: 1.2, 5) is spent before being diagnosed with positive GI cancer. The probability that a “positive GI diagnosis” is next after the state of “incomplete investigation” is 17%, compared with 11% when it is followed in the state of negative GI cancer. Defining the survival as the event of not being in the state of “positive GI cancer,” the survival rate of IDA patients with negative GI cancer is always higher than those with incomplete investigations. Finally, being diagnosed with positive GI cancer is always preceded by the prediction of being considered “very high risk” at the earlier visit. Conclusion: A baseline model was proposed to represent episodes of care for IDA patients at a secondary care center. Preliminary results highlight the importance of completing the GI investigations, especially in IDA patients, who are at high risk of GI cancer and fit to go through the investigations.
- Open Access
- 15 December 2021
- Published by Springer Nature in Diagnostic and Prognostic Research
- Vol. 5 (1) , 1-11
Broad external validation of a multivariable risk prediction model for gastrointestinal malignancy in iron deficiency anaemia
Background: Using two large datasets from Dorset, we previously reported an internally validated multivariable risk model for predicting the risk of GI malignancy in IDA—the IDIOM score. The aim of this retrospective observational study was to validate the IDIOM model using two independent external datasets. Methods: The external validation datasets were collected, in a secondary care setting, by different investigators from cohorts in Oxford and Sheffield derived under different circumstances, comprising 1117 and 474 patients with confirmed IDA respectively. The data were anonymised prior to analysis. The predictive performance of the original model was evaluated by estimating measures of calibration, discrimination and clinical utility using the validation datasets. Results: The discrimination of the original model using the external validation data was 70% (95% CI 65, 75) for the Oxford dataset and 70% (95% CI 61, 79) for the Sheffield dataset. The analysis of mean, weak, flexible and across the risk groups’ calibration showed no tendency for under or over-estimated risks in the combined validation data. Decision curve analysis demonstrated the clinical value of the IDIOM model with a net benefit that is higher than ‘investigate all’ and ‘investigate no-one’ strategies up to a threshold of 18% in the combined validation data, using a risk cut-off of around 1.2% to categorise patients into the very low risk group showed that none of the patients stratified in this risk group proved to have GI cancer on investigation in the validation datasets. Conclusion: This external validation exercise has shown promising results for the IDIOM model in predicting the risk of underlying GI malignancy in independent IDA datasets collected in different clinical settings.
- 15 December 2021
- Published by Springer Nature in Diagnostic and Prognostic Research
- Vol. 5 (1) , 1-11
Open AccessBroad external validation of a multivariable risk prediction model for gastrointestinal malignancy in iron deficiency anaemia
Background: Using two large datasets from Dorset, we previously reported an internally validated multivariable risk model for predicting the risk of GI malignancy in IDA—the IDIOM score. The aim of this retrospective observational study was to validate the IDIOM model using two independent external datasets. Methods: The external validation datasets were collected, in a secondary care setting, by different investigators from cohorts in Oxford and Sheffield derived under different circumstances, comprising 1117 and 474 patients with confirmed IDA respectively. The data were anonymised prior to analysis. The predictive performance of the original model was evaluated by estimating measures of calibration, discrimination and clinical utility using the validation datasets. Results: The discrimination of the original model using the external validation data was 70% (95% CI 65, 75) for the Oxford dataset and 70% (95% CI 61, 79) for the Sheffield dataset. The analysis of mean, weak, flexible and across the risk groups’ calibration showed no tendency for under or over-estimated risks in the combined validation data. Decision curve analysis demonstrated the clinical value of the IDIOM model with a net benefit that is higher than ‘investigate all’ and ‘investigate no-one’ strategies up to a threshold of 18% in the combined validation data, using a risk cut-off of around 1.2% to categorise patients into the very low risk group showed that none of the patients stratified in this risk group proved to have GI cancer on investigation in the validation datasets. Conclusion: This external validation exercise has shown promising results for the IDIOM model in predicting the risk of underlying GI malignancy in independent IDA datasets collected in different clinical settings.